Zobrazeno 1 - 10
of 73
pro vyhledávání: ''
Autor:
Mengmeng Zhu, Yuansheng Liu, Qiong Zhang, Yinan Yang, Wencong Tian, Lei Yang, Jie Liu, Liang Yang, Yanna Shen, Jing Li, Zhi Qi
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:93-103
In our previous study, we discovered that resveratrol (RSV) had potential tumor-promoting effect on pancreatic cancer (PaCa) via up-regulation of VEGF-B. Therefore, we assumed that a pharmacological inhibitor of VEGF-B should potentiate the anti-tumo
Autor:
Laurens van Houdt, Niek F H N van Bree, Yvonne M.H. Versleijen-Jonkers, Winette T. A. van der Graaf, Emmy D.G. Fleuren, Janet Shipley, Melissa H.S. Hillebrandt-Roeffen, Thomas Mentzel, Uta Flucke, Ingrid M.E. Desar, Anke E M van Erp
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, 146, 1659-1670
Journal of Cancer Research and Clinical Oncology, 146, 7, pp. 1659-1670
Journal of Cancer Research and Clinical Oncology, 146, 1659-1670
Journal of Cancer Research and Clinical Oncology, 146, 7, pp. 1659-1670
Purpose Desmoplastic small round cell tumors (DSRCTs) are highly malignant and very rare soft tissue sarcomas with a high unmet need for new therapeutic options. Therefore, we examined poly(ADP-ribose) polymerase 1 (PARP1) and Schlafen-11 (SLFN11) ex
Autor:
Bryan Oronsky, Christopher A. Larson, Christina Brzezniak, Corey A. Carter, Tony R. Reid, Pedro Cabrales, Arnold L. Oronsky
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 143:1671-1677
RRx-001, a minimally toxic tumor-associated macrophage and neutrophil-repolarizing agent, is under investigation in Phase II clinical trials as a sensitizer/resensitizer to cisplatin and carboplatin. On the basis of anecdotal clinical observations of
Autor:
G. Voelcker
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 142:1183-1189
SUM-IAP has been developed with the aim to optimize therapeutic response and minimize toxic reactions of oxazaphosphorine cytostatics. In therapy tests in mice, the primary tumor was successfully eradicated, but animals died due to formation of letha
Publikováno v:
Journal of cancer research and clinical oncology. 145(2)
Multiple myeloma (MM) remains incurable. The MM microenvironment supports MM cells’ survival and immune escape. Because myeloid-derived suppressor cells (MDSCs) is important in the MM microenvironment, and demethylating agent decitabine (DAC) can d
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 141:465-474
Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma that shows malignant effusion most commonly seen in advanced AIDS patients. In this study, we clarified the potential role of VEGF and IL-6 in PEL fluid retention and ev
Autor:
Xiumei Zhou, Yigang Wang, Buyun Ma, Huang Panpan, Caixia Cui, Xinyuan Liu, Rong Zhang, Yanchun Wang, Tao Liu
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 141:419-429
The potent anticancer efficacy of oncolytic viruses has been verified in Clinic in recent years. Cisplatin (DDP) is one of most common chemotherapeutic drugs, but is accompanied by side effects and drug resistance. Our previous studies have shown the
Autor:
Manabu Miki, Manabu Kato, Yoshiki Sugimura, Kiminobu Arima, Shinya Kajiwara, Izumi Matsuoka, Hideki Kanda, Kenichiro Ishii, Takeshi Sasaki, Taizo Shiraishi
Publikováno v:
Journal of cancer research and clinical oncology. 144(1)
Docetaxel (DTX) is a standard chemotherapeutic drug for castration-resistant prostate cancer (CRPC), although adverse events are common. To overcome this problem, researchers have evaluated the efficacy of DTX treatment in combination with other drug
Publikováno v:
Journal of cancer research and clinical oncology. 143(8)
The immunoregulatory effect of demethylating agent decitabine (DAC) has been recognized recently. However, little is known about its impact on immune tolerance. In this study, we aimed to determine the impact of DAC on the immune tolerance induced by
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 138:2137-2143
The aim of the study was to evaluate the effect of the agent SU-11248 (sunitinib malate) in the course from non-castration to castration LNCaP xenograft prostate tumors. BALB/c nude mice were injected with human androgen-dependent prostate cancer cel